X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition provides Rocket with Renovacor’s most advanced program, REN-001, an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a severe form of heart failure.
Lead Product(s): REN-001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: REN-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Rocket Pharmaceuticals
Deal Size: $53.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 01, 2022
Details:
REN-001 is an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a severe form of heart failure.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: REN-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
The research collaboration will focus on a protein discovered by University of Utah scientists that has the potential to address multiple genetic segments of ACM. The new program is being developed as an AAV-based gene therapy to treat potentially life-threatening arrhythmias.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 12, 2022
Details:
REN-001 is an AAV-based gene therapy designed to directly address the underlying cause of BAG3‑associated dilated cardiomyopathy (BAG3-DCM) by using a validated AAV9 capsid to deliver a functional copy of the BAG3 gene to cardiac tissue.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: REN-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
